{"id":61369,"date":"2026-03-26T14:34:41","date_gmt":"2026-03-26T06:34:41","guid":{"rendered":"https:\/\/flcube.com\/?p=61369"},"modified":"2026-03-26T14:34:42","modified_gmt":"2026-03-26T06:34:42","slug":"innocare-pharma-reports-2025-profitability-revenue-surges-135-to-rmb-2-37b-on-global-bd-success","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61369","title":{"rendered":"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success"},"content":{"rendered":"\n<p><strong>InnoCare Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>) announced <strong>2025 financial results<\/strong>, achieving <strong>first-ever annual profitability<\/strong> with <strong>net profit of RMB 640 million (USD 92.7 million)<\/strong>. Revenue <strong>skyrocketed 135.3% YoY to RMB 2.37 billion (USD 343 million)<\/strong>, driven by <strong>core product commercialization growth<\/strong> and <strong>significant global business development (BD) contributions<\/strong>. The results validate InnoCare&#8217;s <strong>globalization strategy<\/strong> through <strong>two major out-licensing transactions<\/strong> and set the stage for <strong>ADC pipeline expansion in 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\">Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YoY Change<\/th><th>Strategic Driver<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 2.37 billion (USD 343M)<\/td><td><strong>+135.3%<\/strong><\/td><td>Core product sales + BD deal economics<\/td><\/tr><tr><td><strong>Net Profit<\/strong><\/td><td>RMB 640 million (USD 92.7M)<\/td><td><strong>First profitable year<\/strong><\/td><td>Operating leverage from commercial scale + upfront\/milestone payments<\/td><\/tr><tr><td><strong>Profitability Milestone<\/strong><\/td><td>Turned profitable<\/td><td>\u2014<\/td><td>Transition from R&amp;D-focused to commercially sustainable biotech<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-business-development-bd-execution\">Global Business Development (BD) Execution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Transaction<\/th><th>Partner<\/th><th>Asset\/Scope<\/th><th>Timing<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Zenas Licensing<\/strong><\/td><td>Zenas Bio<\/td><td><strong>Orelabrutinib<\/strong> + autoimmune disease pipeline<\/td><td>October 2025<\/td><td><strong>Major global partnership<\/strong> \u2013 BTK inhibitor expansion beyond oncology<\/td><\/tr><tr><td><strong>Prolium Deal<\/strong><\/td><td>Prolium Bio<\/td><td><strong>ICP-B02 (PRO-203)<\/strong> + equity arrangement<\/td><td>2025<\/td><td><strong>Value-sharing through equity<\/strong>; fosters mutual benefits in B-cell autoimmunity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>ICP-B02 (PRO-203) Progress:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Single ascending dose (SAD)<\/strong> dosing initiated in healthy subjects (March 2026)<\/li>\n\n\n\n<li><strong>Phase I\/II international multicenter study<\/strong> in <strong>systemic sclerosis (SSc)<\/strong> \u2013 <strong>Q2 2026 initiation<\/strong><\/li>\n\n\n\n<li><strong>Additional studies<\/strong> in severe B-cell-driven autoimmune diseases \u2013 <strong>H2 2026<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-expansion-adc-focus-2026\">Pipeline Expansion: ADC Focus 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Initiative<\/th><th>Target<\/th><th>Timeline<\/th><th>Strategic Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>IND Filings<\/strong><\/td><td><strong>At least 2 innovative ADC drugs<\/strong><\/td><td>2026<\/td><td><strong>Solid tumor differentiation<\/strong> \u2013 expands beyond BTK\/franchise into next-gen oncology<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Solid tumors (specific targets undisclosed)<\/td><td>\u2014<\/td><td>ADCs represent <strong>$10+ billion global market<\/strong>; InnoCare leverages small molecule expertise in payload-linker chemistry<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-globalization-execution\">Strategic Context: Globalization Execution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue Diversification<\/strong><\/td><td><strong>BD now ~30\u201340% of revenue<\/strong> vs. 100% product sales historically \u2013 reduces single-asset risk<\/td><\/tr><tr><td><strong>Global Value Unlock<\/strong><\/td><td>Orelabrutinib autoimmune expansion (Zenas) + ICP-B02 systemic sclerosis (Prolium) demonstrate <strong>platform technology transferability<\/strong><\/td><\/tr><tr><td><strong>Profitability Sustainability<\/strong><\/td><td>RMB 640M profit supports <strong>self-funded R&amp;D<\/strong> \u2013 reduced dependency on equity financing<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td><strong>First China biotech<\/strong> to achieve profitability primarily through <strong>global BD + commercial execution<\/strong> (vs. domestic market only)<\/td><\/tr><tr><td><strong>2026 Catalysts<\/strong><\/td><td>ADC INDs, orelabrutinib autoimmune data, ICP-B02 Phase I\/II readouts<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cash Position:<\/strong> Strong 2025 cash flow supports <strong>3+ years runway<\/strong> for ADC pipeline and global clinical development<\/li>\n\n\n\n<li><strong>Valuation Impact:<\/strong> Profitability + global BD validation likely to support <strong>HKG\/SHA share price premium<\/strong> vs. pre-revenue biotech peers<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding 2026 IND filings, clinical trial initiation, and sustained profitability for InnoCare Pharma. Actual results may differ due to clinical trial execution risks, BD deal milestone timing, and competitive dynamics in the BTK inhibitor and ADC oncology markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61370,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,919,327],"class_list":["post-61369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-9969","tag-innocare-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with net profit of RMB 640 million (USD 92.7 million). Revenue skyrocketed 135.3% YoY to RMB 2.37 billion (USD 343 million), driven by core product commercialization growth and significant global business development (BD) contributions. The results validate InnoCare&#039;s globalization strategy through two major out-licensing transactions and set the stage for ADC pipeline expansion in 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61369\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with net profit of RMB 640 million (USD 92.7 million). Revenue skyrocketed 135.3% YoY to RMB 2.37 billion (USD 343 million), driven by core product commercialization growth and significant global business development (BD) contributions. The results validate InnoCare&#039;s globalization strategy through two major out-licensing transactions and set the stage for ADC pipeline expansion in 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61369\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-26T06:34:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-26T06:34:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success\",\"datePublished\":\"2026-03-26T06:34:41+00:00\",\"dateModified\":\"2026-03-26T06:34:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2601.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 9969\",\"InnoCare Pharma\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61369#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61369\",\"name\":\"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2601.webp\",\"datePublished\":\"2026-03-26T06:34:41+00:00\",\"dateModified\":\"2026-03-26T06:34:42+00:00\",\"description\":\"InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with net profit of RMB 640 million (USD 92.7 million). Revenue skyrocketed 135.3% YoY to RMB 2.37 billion (USD 343 million), driven by core product commercialization growth and significant global business development (BD) contributions. The results validate InnoCare's globalization strategy through two major out-licensing transactions and set the stage for ADC pipeline expansion in 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61369\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2601.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61369#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with net profit of RMB 640 million (USD 92.7 million). Revenue skyrocketed 135.3% YoY to RMB 2.37 billion (USD 343 million), driven by core product commercialization growth and significant global business development (BD) contributions. The results validate InnoCare's globalization strategy through two major out-licensing transactions and set the stage for ADC pipeline expansion in 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61369","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success","og_description":"InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with net profit of RMB 640 million (USD 92.7 million). Revenue skyrocketed 135.3% YoY to RMB 2.37 billion (USD 343 million), driven by core product commercialization growth and significant global business development (BD) contributions. The results validate InnoCare's globalization strategy through two major out-licensing transactions and set the stage for ADC pipeline expansion in 2026.","og_url":"https:\/\/flcube.com\/?p=61369","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-26T06:34:41+00:00","article_modified_time":"2026-03-26T06:34:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61369#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61369"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success","datePublished":"2026-03-26T06:34:41+00:00","dateModified":"2026-03-26T06:34:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61369"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61369#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2601.webp","keywords":["Finanical Reports","HKG: 9969","InnoCare Pharma"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61369#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61369","url":"https:\/\/flcube.com\/?p=61369","name":"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61369#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61369#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2601.webp","datePublished":"2026-03-26T06:34:41+00:00","dateModified":"2026-03-26T06:34:42+00:00","description":"InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with net profit of RMB 640 million (USD 92.7 million). Revenue skyrocketed 135.3% YoY to RMB 2.37 billion (USD 343 million), driven by core product commercialization growth and significant global business development (BD) contributions. The results validate InnoCare's globalization strategy through two major out-licensing transactions and set the stage for ADC pipeline expansion in 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61369#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61369"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61369#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2601.webp","width":1080,"height":608,"caption":"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61369#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma Reports 2025 Profitability \u2013 Revenue Surges 135% to RMB 2.37B on Global BD Success"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61369"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61369\/revisions"}],"predecessor-version":[{"id":61371,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61369\/revisions\/61371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61370"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}